Methylfolate + B12 stack — The Methylation Cycle Optimiser

L-methylfolate (5-MTHF) and methylcobalamin act synergistically in the methionine cycle. 5-MTHF serves as the primary methyl donor, while methylcobalamin acts as an essential cofactor for the enzyme methionine synthase. Together, they facilitate the remethylation of homocysteine into methionine, which is subsequently converted into S-adenosylmethionine (SAMe), the universal methyl donor for DNA, RNA, and protein methylation. Deficiencies in either nutrient can lead to a 'methylfolate trap,' stalling the cycle, elevating neurotoxic homocysteine, and impairing epigenetic regulation.

The VITACOG trial demonstrated that high-dose B-vitamin supplementation (including folic acid and B12) significantly slowed the rate of brain atrophy and cognitive decline in older adults with mild cognitive impairment, particularly those with elevated baseline homocysteine. The FACIT trial similarly showed that 3-year folic acid supplementation improved cognitive function in older adults with raised homocysteine. Recent studies increasingly favour the active, methylated forms (L-methylfolate and methylcobalamin) to bypass common genetic polymorphisms like MTHFR C677T.

Common longevity and cognitive support protocols use 400–1,000 mcg of L-methylfolate combined with 500–1,000 mcg of methylcobalamin daily. Doses are often titrated based on blood homocysteine levels, targeting an optimal range of 6–8 µmol/L. Best taken in the morning, as B vitamins can occasionally cause insomnia if taken late in the day.

Generally well tolerated, but over-supplementation with methylated vitamins can cause 'overmethylation' symptoms in sensitive individuals, including anxiety, irritability, insomnia, and headaches. High-dose folate supplementation without adequate B12 can mask the haematological symptoms of B12 deficiency while allowing irreversible neurological damage to progress, making the combined stack crucial.

Key Papers